cencora

U.S. Biosimilar Landscape

Developed by:

Brian Biehn
Senior Director, Biosimilars

Dennis Nelson
Director, Biosimilars

About this report

Biosimilars are a promising product category, one that can provide patients and doctors with more affordable treatment options.

To date, there have been 69 approvals and 49 launches in the U.S. biosimilar market. As this market matures, its pipeline continues to grow. This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market.

The market landscape chart is grouped by therapeutic class with Biosimilars and Follow-on Biologics organized in columns under the relevant molecule and Reference Product. Additional information regarding interchangeability designation ● and unbranded versions ▲ is highlighted via symbols.

The market pipeline charts show products that have not received FDA approval and are expected to launch in 1 to 4 years. These charts suggest a bright future for biosimilars, as they document a large number of existing and new suppliers investing in biosimilars.

U.S. biosimilar market landscape

As of April 1, 2025

▲ Unbranded version is also available

● Interchangeability approval by the FDA. For more details on interchangeability, please visit https://www.fda.gov/media/151094/download

Approved but yet to launch

Class	Supportive care			Oncology			Insulin			Ophthalmology	
Molecule	Filgrastim	Epoetin	Pegfilgrastim	Rituximab	Bevacizumab	Trastuzumab	Insulin Glargine	Insulin Lispro	Insulin Aspart	Ranibizumab	Aflibercept
Reference Products Manufacturer	NEUPOGEN Amgen	EPOGEN/ PROCRIT Amgen/J&J	NEULASTA Amgen	RITUXAN Genentech	AVASTIN Genentech	HERCEPTIN Genentech	LANTUS ▲ Sanofi	HUMALOG ▲ Lilly	NOVOLOG ▲ Nordisk	LUCENTIS Genentech	EYLEA Regeneron
Biosimilar Products Manufacturer Launch date or approval date	ZARXIO Sandoz Sep 2015	RETACRIT Pfizer-Vifor Nov 2018	FULPHILA Biocon Jul 2018	TRUXIMA Teva Nov 2019	MVASI Amgen Jul 2019	KANJINTI Amgen Jul 2019	▲ ● SEMGLEE Biocon Nov 2021		MERILOG Sanofi Feb 2025	BYOOVIZ ● Biogen Jul 2022	PAVBLU Amgen Oct 2024
	NIVESTYM Pfizer Oct 2018		UDENYCA Coherus Jan 2019	RUXIENCE Pfizer Jan 2020	ZIRABEV Pfizer Jan 2020	OGIVRI Biocon Nov 2019	● REZVOGLAR Eli Lilly Apr 2023			CIMERLI ● Sandoz Oct 2022	YESAFILI ● Biocon May 2024
	RELEUKO Amneal Nov 2022		ZIEXTENZO Sandoz Nov 2019	RIABNI Amgen Jan 2021	ALYMSYS Amneal Oct 2022	TRAZIMERA Pfizer Feb 2020					OPUVIZ ● Biogen May 2024
	NYPOZI Tanvex Jun 2024		NYVEPRIA Pfizer Dec 2020		VEGZELMA Celltrion Apr 2023	HERZUMA Teva March 2020					AHZANTIVE Formycon Jun 2024
			STIMUFEND Fresenius Feb 2023		AVZIVI Sandoz Dec 2023	ONTRUZANT Organon Apr 2020					ENZEEVU Sandoz Aug 2024
			FYLNETRA Amneal May 2023			HERCESSI Accord Jan 2025					
Follow-on biologics Manufacturer Launch date or approval date							BASAGLAR Eli Lilly Dec 2016	ADMELOG Sanofi Dec 2017			

Continued on next page

U.S. biosimilar market landscape

As of April 1, 2025

▲ Unbranded version is also available

● Interchangeability approval by the FDA. For more details on interchangeability, please visit https://www.fda.gov/media/151094/download

Approved but yet to launch



View detailed landscape of Adalimumab products

Note: Prolia and Xgeva (Denosumab) were approved under the same BLA. While each was approved on a single BLA, brands and biosimilars are listed separately for tracking purposes.

Continued on next page

U.S. biosimilar pipeline landscape

As of April 1, 2025



Note: Pending is defined as any stage of development between BLA/aBLA submission and full FDA approval.
*Rituximab products are also approved for indications outside of oncology such as autoimmune indications.

Continued on next page

U.S. biosimilar pipeline landscape

As of April 1, 2025

Class	Immunomodulators									
Molecule	Infliximab	Etanercept	Ustekinumab	Tocilizumab	Certolizumab	Golimumab	Omalizumab	Vedolizumab	Secukinumab	Abatacept
Reference Products Manufacturer	REMICADE J&J	ENBREL Amgen	STELARA IV/SC J&J	ACTEMRA IV/SC Genentech	CIMZIA UCB	SIMPONI J&J	XOLAIR Genentech	ENTYVIO Takeda	COSENTYX Novartis	ORENCIA BMS
Pipeline Manufacturer Development stage	NI-071 Sagent Ph 3	YLB113 Lupin Ph 3	BAT2206 Hikma–Bio-Thera Pending	DRL_TC Dr. Reddy's Ph 3	XB003 Xbrane Pre-clin	BAT2506 Bio-Thera Ph 3	BP11 Aurobindo Ph 3	PB016 Polpharma Ph 3	BAT2306 Bio-Thera Ph 3	DRL_AB Dr. Reddy's Ph 3
						AVT05 Alvotech Pending	ADL-018 Amneal Ph 3	AVT16 Alvotech-Teva Ph 3	CT-P55 Celltrion Ph 3	
							TEV-45779 Teva Ph 3			

Note: Pending is defined as any stage of development between BLA/aBLA submission and full FDA approval.

Continued on next page

U.S. biosimilar pipeline landscape

As of April 1, 2025



Note: Pending is defined as any stage of development between BLA/aBLA submission and full FDA approval.
* Indicates that a biosimilar product has a different route of administration than its innovator product.

▲ Unbranded version is also available

● Interchangeability approval by the FDA. For more details on interchangeability, please visit https://www.fda.gov/media/151094/download

New biosimilar launches

Reference products included have no marketed biosimilars





Definitions

Product	Definition
Reference products[1]	A reference product is a single biological product, already licensed (approved) by the FDA under section 351(a) of the Public Health Service Act, against which a proposed biosimilar or interchangeable product is compared. A reference product is approved based on, among other things, a full complement of safety and effectiveness data.
Biosimilars[1]	A biosimilar product is a biological product that is highly similar to and has no clinically meaningful differences in terms of safety or effectiveness from an existing FDA-licensed (approved) reference product.
Interchangeable biosimilars[1]	An interchangeable product is a biological product that meets the requirements for a biosimilar product and is approved based on information that is sufficient to show that it can be expected to produce the same clinical result as the reference product in any given patient; and for a biological product that is administered more than once to an individual, there is not a greater safety risk or risk of reduced efficacy from alternating or switching between use of the interchangeable product and its reference product. An interchangeable product can be substituted for the reference product without the intervention of the prescribing healthcare provider.
Unbranded reference products[1]	An unbranded reference product generally describes an approved brand name biological product that is marketed under its approved BLA without its brand name (proprietary name) on its label. An “unbranded reference product” is not an “interchangeable biosimilar.” However, an unbranded reference product is considered by the FDA to be equivalent to its brand name biological product because it is the same product as the brand name biological product under the same BLA.
Follow-on biologics	A follow-on biologic is a competing brand product to a reference product and was approved under an NDA pathway before the biosimilar approval pathway (351k) was available.

Key: BLA – Biologics License Application; FDA – Food and Drug Administration; NDA – New Drug Application.

1. FDA. Purple Book. Last updated October 24, 2023. Accessed November 3, 2023. https://purplebooksearch.fda.gov/

Find out how Cencora is creating sustainability and longevity for biosimilars.

For more information, please contact us here.

Brian Biehn
Senior Director, Biosimilars
Cencora

Dennis Nelson
Director, Biosimilars
Cencora